IL17A and Miyoshi myopathy: The multivariate regression analysis indicated that serum IL-17A levels were independently correlated with baseline bone lesions in MM patients (β = 0.15; 95% CI (0.09, 0.21); p < 0.0001) and fractures (OR = 1.18; 95% CI (1.06, 1.31); p < 0.0001) (Table 2).